Novavax (NVAX) Net Cash Flow (2010 - 2026)

Novavax's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$23.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 91.32% year-over-year to -$23.1 million; the TTM figure through Mar 2026 stood at -$52.4 million (up 75.26% YoY), while the FY2025 annual figure was -$295.2 million, down 860.89% from the prior year.
• Net Cash Flow was -$23.1 million for Q1 2026 at Novavax, up from -$25.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $199.8 million in Q2 2024 to a low of -$703.5 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$76.5 million across 5 years, with a median of -$32.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow tumbled 1390.19% in 2023, then jumped 268.76% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $51.6 million in 2022, then sank by 265.77% to -$85.5 million in 2023, then surged by 61.88% to -$32.6 million in 2024, then climbed by 21.43% to -$25.6 million in 2025, then grew by 9.81% to -$23.1 million in 2026.
• The last three Net Cash Flow figures came in at -$23.1 million (Q1 2026), -$25.6 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.